Chronic lymphocytic leukaemia: open trials in Sweden

9 open trials have a site in Sweden. Registry data; only the trial team decides who can take part.

NCT06943872
A Study to Investigate Progression-Free Survival With Sonrotoclax Plus Obinutuzumab Or Sonrotoclax Plus Rituximab Compared With Venetoclax Plus Rituximab Treatment In Patients With Relapsed and/or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CELESTIAL-RRCLL)
Trial Treatment · Phase 3 · BeOne Medicines
Sahlgrenska University Hospital-Vaestra Goetalandsregionen, Gothenburg · Lund University Hospital, Lund · Karolinska University Hospital, Solna · Uppsala University Hospital, Uppsala
Registry updated 2026-10-23
NCT06136559
A Study of Nemtabrutinib (MK-1026) Versus Comparator (Investigator's Choice of Ibrutinib or Acalabrutinib) in First Line (1L) Chronic Lymphocytic Leukemia (CLL)/ Small Lymphocytic Lymphoma (SLL) (MK-1026-011/BELLWAVE-011)
Trial Treatment · Phase 3 · Merck Sharp & Dohme LLC
Karolinska University Hospital, Solna
Registry updated 2026-10-13
NCT03934372
Safety and Efficacy of Ponatinib for Treatment of Pediatric Recurrent or Refractory Leukemias, Lymphomas or Solid Tumors
Trial Treatment · Phase 1/2 · Incyte Biosciences International Sàrl
Karolinska University Hospital, Solna, Stockholm
Registry updated 2026-10-09
NCT07860775
Treatment of Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma With Pirtobrutinib in Combination With Epcoritamab if the Disease Comes Back After Previous Treatment.
Trial Treatment · Phase 2 · Stichting Hemato-Oncologie voor Volwassenen Nederland
SE-Orebro-Orebro UH, Örebro
Registry updated 2026-10-06
NCT05006716
A Dose-Escalation and Expansion Study of Tacabrutideg (BGB-16673) in Participants With B-Cell Malignancies
Trial Treatment · Phase 1/2 · BeOne Medicines
Sahlgrenska University Hospital Hematology, Gothenburg · Karolinska Universitetssjukhuset Solna, Stockholm
Registry updated 2026-10-05
2023-510294-34-00
A phase 3 multicenter, randomised, prospective, open-label trial of fixed-duration (12 cycles) venetoclax/ obinutuzumab vs. fixed-duration (15 cycles) venetoclax/ pirtobrutinib vs. MRD-guided venetoclax/ pirtobrutinib in patients with previously untreated chronic lymphocytic leukaemia (CLL)/ small lymphocytic lymphoma (SLL) aiming to establish measurement of individual residual disease for adjustment of treatment duration to improve outcomes (CLL18/ MOIRAI)
Trial Treatment · Phase 3 · University Of Cologne
Region Dalarna, Falun · Sahlgrenska University Hospital-Vaestra Goetalandsregionen, Gothenburg · Region Halland, Halmstad · Region Oestergoetland, Linkoping · Region Skane Skanes Universitetssjukhus, Lund · Örebro University Hospital, Örebro · Region Vaesterbotten, Umea · Uppsala University Hospital, Uppsala
Registry updated 2026-10-01
NCT06973187
A Study to Evaluate the Safety and Efficacy of Tacabrutideg (BGB-16673) Compared to Pirtobrutinib in Adults With Relapsed/Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
Trial Treatment · Phase 3 · BeOne Medicines
Sahlgrenska University Hospital-Vaestra Goetalandsregionen, Gothenburg · Karolinska University Hospital, Solna
Registry updated 2026-09-28
NCT07277231
A Study to Investigate Sonrotoclax (BGB-11417) Plus Zanubrutinib (BGB-3111) Compared With Venetoclax Plus Acalabrutinib in Adults With Previously Untreated Chronic Lymphocytic Leukemia
Trial Treatment · Phase 3 · BeOne Medicines
Karolinska University Hospital, Solna
Registry updated 2026-09-28
NCT04771507
A Pilot Study on Intermittent Ibrutinib in Patients With Advanced-phase Chronic Lymphocytic Leukemia (CLL)
Trial Treatment · Phase 1/2 · Jeanette Lundin
Falu Lasarett, Falun · Gävle Hospital, Gävle · Sahlgrenska University Hospital, Gothenburg · Skåne University Hospital, Lund · Örebro University Hospital, Örebro · Karolinska University Hospital, Stockholm · Norrland's University Hospital, Umeå · Akademiska hospital, Uppsala
Registry updated 2021-02-25

All Chronic lymphocytic leukaemia trials and the map

This page is not medical advice. Talk to your doctor before contacting a trial.

Report an error